» Articles » PMID: 25586068

[Parkinson's Disease and Psychoses]

Overview
Journal Neuropsychiatr
Specialties Neurology
Psychiatry
Date 2015 Jan 15
PMID 25586068
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Psychotic symptoms are common in Parkinson's disease (PD) and are associated with increased disability, worsened quality of life, and poor long-term prognosis. In this article, clinical features, hypotheses on pathogenesis, and current treatment strategies for Parkinson's disease psychosis (PDP) are reviewed. According to epidemiological studies, the prevalence of PDP is between 20 to 40 %. Complex visual hallucinations are the most common psychotic symptoms and are present in 17-72 % of the patients. Other sensory disturbances encompass tactile hallucinations and minor hallucinatory phenomena, such as sense of presence and visual illusions. Hallucinations are often accompanied by delusions, whose most frequent themes are persecution and jealousy. The pathophysiology of PDP remains unclear. Different factors have been implicated, including Levo-dopa and dopaminergic medications, neurotransmitter imbalances, neuroanatomic alterations, abnormal visuospatial processes, and genetic predisposition. The first-line strategy in the treatment of persistent and problematic PDP is represented by reduction in anti-PD medications. Second-generation antipsychotics are the treatment of choice, with clozapine being demonstrated as the most effective and tolerable drug for PD patients.

Citing Articles

Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Jellinger K J Neural Transm (Vienna). 2019; 126(8):933-995.

PMID: 31214855 DOI: 10.1007/s00702-019-02028-6.


Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.

Yuan M, Sperry L, Malhado-Chang N, Duffy A, Wheelock V, Farias S Brain Behav. 2017; 7(6):e00639.

PMID: 28638698 PMC: 5474696. DOI: 10.1002/brb3.639.


Psychosis in Parkinson's disease: identification, prevention and treatment.

Levin J, Hasan A, Hoglinger G J Neural Transm (Vienna). 2015; 123(1):45-50.

PMID: 25894288 DOI: 10.1007/s00702-015-1400-x.

References
1.
Aarsland D, Larsen J, Karlsen K, Lim N, Tandberg E . Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999; 14(10):866-74. View

2.
Goetz C, Wuu J, Curgian L, Leurgans S . Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005; 64(1):81-6. DOI: 10.1212/01.WNL.0000148479.10865.FE. View

3.
Kiziltan G, Ozekmekci S, Ertan S, Ertan T, Erginoz E . Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. J Neurol. 2007; 254(4):448-52. DOI: 10.1007/s00415-006-0388-4. View

4.
Friedman A, Sienkiewicz J . Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand. 1991; 84(2):111-3. DOI: 10.1111/j.1600-0404.1991.tb04918.x. View

5.
Whitehouse P . Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson's disease and Alzheimer's disease. Adv Neurol. 1987; 45:393-7. View